The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity
Abstract
BACKGROUND: The transmembrane receptor Fas, together with its protein-binding partner (Fas ligand), is a key regulator of programmed cell death (i.e., apoptosis). Fas and Fas ligand also influence the ability of cytotoxic T lymphocytes and natural killer cells to eliminate tumor cells. However, by inducing apoptosis in activated T cells, the Fas/Fas ligand system may protect some tumor cells from clearance by the immune system. Anticancer drugs enhance Fas ligand expression on the surface of Fas receptor-expressing leukemia cells, thus suggesting that apoptosis caused by these drugs may be mediated via the Fas/Fas ligand system. PURPOSE: This study was conducted to further investigate the relationship between the modulation of Fas receptor gene and protein expression by treatment of cells with cytotoxic drugs and the immune clearance of tumor cells. METHODS: Fas expression on human HT29 colon carcinoma cells treated with a variety of anticancer drugs (cisplatin, doxorubicin, mitomycin C, fluorouracil, and camptothecin) was analyzed by use of quantitative flow cytometry. Human HCT8R and HCT116 colon carcinoma cells and human U937 leukemia cells were treated with cisplatin only and analyzed in the same way. Fas ligand messenger RNA and protein levels were studied by use of a reverse transcription-polymerase chain reaction assay and by flow cytometry. Fas gene expression and messenger RNA levels in cisplatin-treated HT29 cells were characterized by use of in vitro nuclear run-on and northern blot hybridization assays. The cytotoxic activities of agonistic anti-Fas antibodies, Fas ligand, and allogeneic peripheral blood leukocytes, in the absence or presence of Fas-blocking monoclonal antibodies, against tumor cells were assessed by methylene blue staining and chromium-51 release assays. RESULTS: Clinically relevant concentrations of cisplatin, doxorubicin, mitomycin C, fluorouracil, or camptothecin enhanced Fas receptor expression on the plasma membrane of HT29 cells. Cisplatin-mediated increases in Fas expression were confirmed in HCT8R, HCT116, and U937 cells. The enhancement of Fas protein expression was associated with an increased sensitivity of cisplatin-treated tumor cells to agonistic anti-Fas antibodies, to soluble Fas ligand, and to allogeneic peripheral blood leukocyte-mediated cytotoxicity. Each of these effects was blocked by co-treatment of the cells with antagonistic anti-Fas antibody. CONCLUSION AND IMPLICATIONS: In addition to their direct cytotoxic effects, chemotherapeutic drugs sensitize tumor cells to Fas-mediated cytotoxicity and Fas-dependent immune clearance. On the basis of these findings, new strategies might be developed to improve the efficacy of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Yonehara, S., Ishii, A., & Yonehara, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1747 · Cited by 1,400
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Apoptosis induced by anticancer drugs
Hickman, J. A. (1992) · Cancer and Metastasis Review · doi:10.1007/bf00048059 · Cited by 863
Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity.
Rouvier, E., Luciani, M. F., & Golstein, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.195 · Cited by 787
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Expression of the Fas ligand in cells of T cell lineage.
Suda, T., Okazaki, T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K., & Nagata, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3806 · Cited by 644
Leithäuser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K., Krammer, P. H., & Möller, P. (1993) · PubMed · Cited by 625
French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.335 · Cited by 448
Analysis of Events Associated With Cell Cycle Arrest at G2 Phase and Cell Death Induced by Cisplatin
Sorenson, C. M., Barry, M. A., & Eastman, A. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.9.749 · Cited by 443
Activation of programmed cell death by anticancer agents: cisplatin as a model system.
Eastman, A. R. (1990) · PubMed · Cited by 398
Fas-mediated cytotoxicity by freshly isolated natural killer cells.
Arase, H., Arase, N., & Saito, T. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1235 · Cited by 362
Möller, P., Koretz, K., Leithäuser, F., Brüderlein, S., Henne, C., Quentmeier, A., & Krammer, P. H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570314 · Cited by 306
Owen‐Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K. K., & Yonehara, S. (1994) · PubMed · Cited by 258
Fas expression and function in normal and malignant breast cell lines.
Keane, M., Ettenberg, S. A., Lowrey, G. A., RUSSELL, E. K., & Lipkowitz, S. (1996) · PubMed · Cited by 231
The Role of APO‐1‐Mediated Apoptosis in the Immune System
Krammer, P. H., Dhein, J., Walczak, H., Behrmann, I., Mariani, S., Matiba, B., Fath, M., Daniel, P. T., Knipping, E., Westendorp, M. O., et al. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00889.x · Cited by 225
Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells
Oshimi, Y., Oda, S., Honda, Y., Nagata, S., & Miyazaki, S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.2909 · Cited by 208
Fas-Mediated Apoptosis in Primary Cultured Mouse Hepatocytes
Ni, R., Tomita, Y., Matsuda, K., Ichihara, A., Ishimura, K., Ogasawara, J., & Nagata, S. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1349 · Cited by 199
Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo
Rensing‐Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S. M., Weller, M., Aebischer, P., Krammer, P. H., & Fontana, A. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250821 · Cited by 191
Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways.
Dubrez, L., Savoy, I., Hamman, A., & Solary, E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00935.x · Cited by 159
Self-citationMonoclonal-antibody-mediated apoptosis in adult T-cell leukaemia
Debatin, K., Krammer, P. H., Goldman, C. K., Bamford, R. N., & Waldmann, T. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)90735-n · Cited by 149
Resistance to Fas-mediated apoptosis in human hepatoma cells.
Natoli, G., Ianni, A., Costanzo, A., Petrillo, G. D., Ilari, I., Chirillo, P., Balsano, C., & Levrero, M. (1995) · PubMed · Cited by 148
Kobayashi, N., Hamamoto, Y., Yamamoto, N., Ishii, A., Yonehara, M., & Yonehara, S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.24.9620 · Cited by 118
A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice.
Peng, S. L., Robert, M. E., Hayday, A., & Craft, J. E. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.3.1149 · Cited by 102
Falk, M., Trauth, B. C., Debatin, K., Klas, C., Gregory, C., Rickinson, A. B., Calender, A., Lenoir, G., Ellwart, J., & Krammer, P. (1992) · Blood · doi:10.1182/blood.v79.12.3300.bloodjournal79123300 · Cited by 96
Pharmacokinetics of Cisplatin and Its Monohydrated Complex in Humans
Andersson, A., Fagerberg, J., Lewensohn, R., & Ehrsson, H. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js960037a · Cited by 94
Robertson, M. J., Manley, T. J., Pichert, G., Cameron, C. A., Cochran, K., Levine, H., & Ritz, J. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509051703 · Cited by 91
Martínez‐Lorenzo, M. J., Álava, M. A., Anel, A., Piñeiro, A., & Naval, J. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-782.x · Cited by 90
Dimanche‐Boitrel, M., Pelletier, H., Genne, P., Petit, J., Grimellec, C. L., Canal, P., Ardiet, C. J., Bastian, G., & Chauffert, B. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500502 · Cited by 88
Self-citationMatsue, H., Kobayashi, H., Hosokawa, T., Akitaya, T., & Ohkawara, A. (1995) · Archives of Dermatological Research · doi:10.1007/bf01105085 · Cited by 69
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Cellular stress response and apoptosis in cancer therapy
Herr, I., & Debatin, K.-M. (2001) · Blood · doi:10.1182/blood.v98.9.2603 · Cited by 800
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Clément, M.-V., Hirpara, J. L., Chawdhury, S.-H., & Pervaiz, S. (1998) · Blood · doi:10.1182/blood.v92.3.996 · Cited by 611
Metadata
- Authors
- Micheau, O., Solary, E., Hammann, A., Martin, F., & Dimanche-Boitrel, M.-T.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-06-04
- Volume
- 89
- Issue
- 11
- Pages
- 783-789
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2154063020
- Cited by
- 281
- References
- 38
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.